Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma

Article English OPEN
Shi, Yuankai ; Xu,Jianping ; Liu,Xiaoyan ; Yang,Sheng ; Zhang,Xiangru (2016)
  • Publisher: Dove Press
  • Journal: OncoTargets and Therapy, volume 9, pages 2,911-2,917 (issn: 1178-6930, eissn: 1178-6930)
  • Related identifiers: pmc: PMC4876100, doi: 10.2147/OTT.S102472
  • Subject: OncoTargets and Therapy | brain metastases | brain metastase | lung adenocarcinoma | RC254-282 | Original Research | Icotinib | Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Jianping Xu, Xiaoyan Liu, Sheng Yang, Xiangru Zhang, Yuankai Shi Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China Objective: The objective of this study was to evaluate the efficacy and safety of icotinib in patients with brain metastases (BMs) from lung adenocarcinoma.Patients and methods: Clinical data of 28 cases with BMs from lung adenocarcinoma were retrospectively analyzed. All the patients took 125 mg icotinib orally three times a day. Progression of disease, intolerable adverse reactions, and number of deaths were recorded.Results: For all the patients, the remission rate of icotinib was 67.8% and the disease control rate was 96.4%. The median overall survival time of patients was 21.2 months, and the median progression-free survival time of patients was 10.9 months. Only mild adverse events of grade 1/2 were observed during the treatment.Conclusion: Icotinib was an effective and safe strategy to treat patients with BMs from lung adenocarcinoma.Keywords: icotinib, lung adenocarcinoma, brain metastases 
  • References (39)
    39 references, page 1 of 4

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.

    2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-1380.

    3. Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003;29(6):533-540.

    4. Yawn BP, Wollan PC, Schroeder C, Gazzuola L, Mehta M. Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med. 2003;86(12):32-37.

    5. D'Antonio C, Passaro A, Gori B, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014;6(3):101-114.

    6. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494-500.

    7. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005;23(25): 6207-6219.

    8. Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/ cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology. 2003;64(1):28-35.

    9. Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol. 2012;14(4):491-495.

    10. Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology. 2000;59(4):291-295.

  • Metrics
    No metrics available
Share - Bookmark